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Mutations which cause the inborn errors of mem-
brane transport can provide information about the
normal topology' of renal transepithelial transport.
In recent years various reviews of tubular transport
[1—6] have appeared which discussed the interrelation
between disease and net tubular reabsorption of or-
ganic solutes.2 Their emphasis was primarily on the
functions which served solute transport and less on
the diseases associated with the disturbance of trans-
port. In this review we have taken the opportunity to
describe, and to speculate on, the probable site in the
tubular cell of the defect in transcellular movement of
the solute in a number of inborn errors of tubular
transport. We hope that the speculations will stimu-
late debate, formulation of hypotheses and further
experimental evaluation to advance our knowledge.
The table included in this paper provides a catalogue
of the currently accepted inborn errors of tubular
transport. It is these clinical "windows" which,
through the expression of mutation, have revealed
and helped to delineate an impressive array of spe-
cific transport functions in tubular membrane.
Cellular uptake and transcellular transport
The epithelial cell of the renal tubule has luminal
and basilar poles, with definite orientations to the
fluids in contact with them; its luminal pole faces an
ultrafiltrate of plasma where solute is topologically
outside the body while the basilar pole is in contact
with peritubular interstitial fluid where solute is inside
the body. Cells of the proximal tubule, in both the
Topology—anatomical definition: the structure of a particular
region or part of the body (Webster).
The term "solute" in this paper refers to organic solutes except
when clearly indicated otherwise: for example, in the section on
phosphate reabsorption.
© 1976, by the International Society of Nephrology.
Published by Springer-Verlag New York
149
convoluted and pars recta segments where a major
fraction of electrolyte and organic solute transport
occurs, have a greatly enlarged membranous surface
formed of closely packed microvilli: the latter in-
crease the absorptive surface about forty-fold [7, 8].
Microvilli are associated with an unstirred layer at
the external liquid-solid interface, which is the major
rate-limiting step in trans brush-border permeation at
low concentrations of many solutes [9]. The unstirred
layer also serves as a locale in which enzymes may act
upon substrate, e.g., disaccharides, before transport
[10]. Tubular epithelium is also a continuous sheet by
virtue of punctuate contacts, or tight junctions, be-
tween cells at their luminal poles [11]. These junc-
tions are probably impermeable to organic solutes
under normal conditions. Therefore, the solute must
enter epithelial cells to reach the peritubular space
during reclamative transport and to reach the lumen
during secretory transport. To achieve this vectorial
process, an asymmetry of net solute flux is required
during reclamative and secretory transports. How
mutation informs us about the functional organ-
ization of two sets of membranes (luminal or brush
border, and basolateral) and three pools (luminal,
cellular and peritubular) ordered in series, and how
they achieve these net transtubular fluxes, is of
fundamental interest to us in this brief review.
Cellular uptake ofsolute. The current view of bio-
logical membranes emphasizes a fluid-mosaic, struc-
tural model, in which the proteins form a mosaic in
the bilaminar bed of lipid [12]. In the absence of
diffusion channels, permeation of the plasma mem-
brane by hydrophyllic solutes must be facilitated by
carriers [13]. Certain types of membrane protein ap-
parently serve as carriers [14], thus providing a per-
tinent focus for the effect of mutation on the trans-
port process. Various chemical and kinetic probes
[13] reveal the specificity of carriers and their ability
to recognize solutes. Since the transmembrane move-
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ment of many solutes across the basolateral and
brush border membranes of tubular epithelium, both
in vivo and in vitro, can occur against a chemical
gradient in all parts of the nephron [5, 6], there must
also be an investment of energy in transport in the
form of a conjugate-driving force [15].
Assuming that the solute remains osmotically ac-
tive upon entering the intracellular pool, and there is
no evidence yet to the contrary [16], it follows that
the plasma membrane plays a critical role in the form
of a barrier to exodus after concentrative uptake. A
mechanism for attainment of dynamic asymmetry in
the carrier as it functions on opposite sides of the
membrane is required. A simple kinetic description of
this event is possible [6] (Fig. I). The Michaelis equa-
tion can be used to describe carrier-mediated and
opposing fluxes2 of solute across the membrane
where entry (or influx) and exodus (or efflux) are
described by separate equations:
and
Vmax jflf [S]0
lIlt
Km br + [S]0
Vmax elf [S]1
Ueff
Km elf + [S]1
[S]0 and [S]1 are the concentrations of solute on the
outside and inside of the membrane, respectively.
When uptake is concentrative, influx exceeds efflux
until the steady state is achieved at which time influx
Fig. I. Diagram showing the apparent kinetics of steady-state entry(influx) and exodus (efflux) under conditions of active transport
(accumulation against a chemical gradient) of L-proline across the
plasma membrane of a cell. (See text for appropriate Michaelis
equations and description of terms.) Where the rate of solute entry
is not higher than the rate of its removal by metabolism, the latter
comes to influence transport in the transtubular orientation. Di-
minution of metabolic "runout" may cause the internal solute
concentration to rise (i.e., change from [S]. to [S]lb); when this
change occurs in relation to the luminal membrane, exodus (back-
flux) will increase and egressed solute will be removed by the
flowing column of urine. These considerations may be relevant to
the interpretation of solute loss in some hereditary disorders of
tubular transport and metabolism and to the concept of maximal
rates of tubular absorption (Tm). (From Scriver, Mclnnes and
Mohyuddin [97].)
equals efflux. In the latter state, [S]1 will be >> [SJ0; it
follows from equations 1 and 2 that Km err must then
be >> Km ml The maintenance of this relationship
which is essential to concentrative uptake appears to
be a genetically determined property of the carrier.
Efflux across the luminal membrane occurs during
net absorption of amino acids and glucose by the
proximal tubule [17—19]; this backflux is quite in
keeping with the normal kinetics of efflux depicted in
Fig. 1. However, backflux is necessarily small if con-
centrative uptake is an initial step during net trans-
epithelial reclamation of solute, as is now known to
be the case for the transport of some amino acids and
for glucose [17—19].
The ability to generate asymmetry in transcellular
movement of solute, so that a vectorial flux occurs,
has long been a subject of interest [20]. Transport
across epithelium has many features which are analo-
gous to transport across the plasma membrane;
but transepithelial transport also has unique char-
(I) acteristics which distinguish it from simple up-
take into cells. In tubular epithelium the now well-
recognized substrate specificity of the transport proc-
ess, presumably invested in the transport proteins or
(2) reactive sites of the plasma membrane [13], and urn-
ned by the appropriate kinetic, chemical and genetic
probes [1—6], is not necessarily identical at opposite
poles of the transporting cell. Uptake into the in-
tracellular pool, as defined by equations I and 2, can
pertain to both luminal and basilar and lateral mem-
branes. However, if an identical net flux exists at both
sets of membranes, net transcellular flux, from urine
to peritubular space, or the reverse would not occur.
For example, unless the unidirectional flux of solute
outward at the basilar pole of the cell is greater than
the unidirectional flux outward at the luminal pole,
there is nothing to prevent achievement of a trans-
cellular steady state so that backflux becomes the
equal of entry at the luminal site serving uptake from
glomerular ultrafiltrate, thus making net absorptive
transport impossible. During absorption, a mecha-
nism must be found which maintains the interim
instantaneous uptake ratio below the "true" steady-
state ratio across the luminal membrane; therefore,
an explanation for "run out" from the intracellular
space in the direction of the peritubular space is
required. Two mechanisms seem plausible. 1) Meta-
bolism. If there is a large intracellular pool of the
solute, membrane transport will not be the rate-limit-
ing step in its transcellular movement. The rate of its
intracellular utilization will determine its intracellular
concentration and, therefore, the number of mole-
cules of the original solute species available for back-
flux after uptake. It follows that a disturbance of
l/Ks 1/Ks. [S1b] [Sal [S0] 1/EPro]
\ Blood
o"%
Urine
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intracellular metabolism may perturb tubular ab-
sorption through modulation of intracellular pooi
size. Currently available techniques which measure
net reabsorption and transepithelial movement are,
in essence, "black box" methods which largely fail to
account for intracellular events acting on solute. 2)
Dissimilar characteristics of luminal and basilar mem-
branes. Luminal and basilar membranes are dis-
similar both in their morphologic and functional
characteristics. Differences at the two poles have been
described, for example, in electropotential [21], and
in the uptake of amino acids [18, 22—25] sugars [19,
26, 27] and keto acids [28]. This functional
asymmetry clearly permits metabolically inert amino
acids, which have no "run out" into other metabolic
pools, to be reclaimed from urine into blood against a
chemical gradient [29]. Accordingly, proximal tubule
reclamation may be accomplished by a more per-
missive efflux at the basilar membrane relative to the
luminal pole. Relatively little work has been done to
examine the role of solute removal by peritubular
blood flow in relation to urine flow, and the relation
this may have to transtubular transport kinetics.
We should recognize also that solutes such as,
amino acids [6, 30, 31] and glucose [19] which are
taken up from peritubular fluid in many portions [16,
26, 27] of the nephron evidently experience only min-
imal net efflux across the luminal membrane and do
not appear in bladder urine in significant amounts.
Further evidence for diversification of transport in
brush border and basolateral membranes in various
parts of the nephron is seen in the distal tubule, which
takes up amino acids, not at all from the lumen and
only slowly from peritubular fluid [6].
Functional classification of
inborn errors of tubular transport
Two membranes and three solute pools, arranged
in series, accommodate transepithelial transport. In
principle, the various inborn errors of reclamative
transport can then be assigned to specific disorders of
membrane function according to Fig. 2. Mutation
can effect tubular reabsorption at the following
stages: JA) uptake activity (entry) at the luminal
carrier; JB) backflux (luminal exodus) permitted on
the carrier; 2) cellular utilization of absorbed solute
(pool size) controlled by its metabolic disposal; 3)
unidirectional flux from cell to peritubular fluid at
basilar and lateral membranes (peritubular exodus).
Disorders of secretory transport can also be served
by this model with due consideration for the pre-
dominant direction of the fluxes.
Hormone-dependent inborn errors of tubular
Fig. 2. A model delineating possible sites for expression of mutant
alleles causing hereditary disorders of tubular reabsorption. Appro-
priate recognition of the vectorial flux in secretory transport allows
the mode! to be adapted also to disorders of secretion. Defect IA,
mutant site (carrier) blocks entry; defect !B, mutant carrier per-
mits excessive exodus (backflux) from internal pool (); defect 2,
blocked catabolic mutant state prevents metabolic "runout" to
alternate form (0) leading to accumulation of original solute in
the internal pool (A) and exaggerated exodus (backflux) on normal
carrier; defect 3, defect in exodus at basilar (or lateral) membrane
leads to intracellular accumulation as in defect 2. All lead to
reduction of net transepithelial flux. Not shown are hormone-
modulated defects involving hormone binding at specific sites on
the basilar membrane, and transduction of signal by internal mes-
senger to influence the primary transport process (e.g., phosphate
transport modulation by parathyroid hormone or calcitonin, and
water transport modulation by vasopressin).
transport require consideration of two additional
steps: 1) binding of hormone to the appropriate
plasma membrane and 2) intracellular translation of
the hormonal signal. We have selected examples
from Table 1 to describe defective mechanisms at
different stages of the transepithelial transport proc-
ess.
IA. Disorders of solute uptake of the luminal mem-
brane. The casual student of biological transport is
likely to assume that the hereditary disorders of tubu-
lar transport express themselves at the luminal mem-
brane. We know from studies of electrolyte transport
that other peritubular membranes play vital roles in
solute migration across the tubule; no direct evidence
for a luminal membrane defect has been obtained in
any disease listed in Table 1; only indirect evidence,
and only in certain disorders of net reclamation, is at
hand. The examples we have chosen will highlight a
number of themes including the diversity of mem-
brane sites used by even a single solute during tubular
transport, and the great specificity among sites ex-
posed to a wide mixture of solutes. Consequently,
mutation is likely to ablate only a fraction of any
given transport function. Diversity has adaptive ad-
vantage.
The Hartnup trait. Typical homozygotes have a
selective impairment in the intestinal and tubular ab-
sorption of a particular group of neutral a-amino
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Cystinuria
(22010)'
Hypercystinuria
(23820)
Iminoglycinuria
(24260)'
Dicarboxylic
aminoaciduria
(glutamate-aspartate
transport defect)
(23165)
-aminoaciduria -
(hypertaurinuria)
See text
Renal glucosuria
(glycosuria)
(03260)'
Glucose-galactose
malabsorption
(23160)'
Bartter syndrome
(hypokalemic
alkalosis) (24120)'
Albright's hereditary
osteodystrophy
(pseudohypopara-
thyroidism, etc.)
(30080)'
Specific system for
cyst(e)ine (uptake)
Shared system for
iminoacids, glycine
(& sarcosine) (uptake)
Intestine
brain?
(skin fibroblasts are
normal
Shared dicarboxylic Intestine
acid transport
system (?)
Glucose carrier Intestine normal
(uptake)
Shared glucose- Intestine
galactose carrier
(uptake)
A Na carrier? Erythrocyte(Na content
increased)
Regulation of Bone
parathyroid hormone
receptor mechanism
(or messenger system)
AD/AR Two alleles (different loci?)
Type 1(22270) protein
intolerance; failure to
thrive, hyperammonemia
(mitochondrial defect?) bets
silent. Type 11(12600)
assoc. with mental retarda-
tion in recently discovered
homoz. Hets have modest
dibasic aminoaciduria.
AR "Negative" reabsorption
of affected amino acid can
occur. Three alleles (same
locus?) each causing differ-
ent phenotypes: in type-I
bets, no excess amino
acids in urine ("silent"); in
type-Ill homoz, intestinal
transport intact.
AR? One pedigree only
AR Four alleles (same locus?)
I, II, silent hets
III, IV hyperglycinuric bets
1, with intestinal defect
IV, Km mutant.
AR Two alleles (same locus?)
l intestine affected; II,
intestine normal. Hets
"silent" in both.
AR
System defined by com-
petitive inhibition in hyper-
fl-alaninemia in man
(McKusick [23740]) (&
taurinuria phenotype in
mouse).
AR Two forms; Km variant
& low-Tm variant (Reubi
type A).
AR Minimal renal glucosuria
and no galactosuria under
usual conditions. Diarrhea
principal symptom; mimics
disaccaridase deficiency
AR Secondary juxtaglomerular
cell hyperplasia, normal
blood pressure, secondary
hyperaldosteronism &
hypokalemic alkalosis
XL (dominant) More then one allele (at
(or sex- different gene loci ?) Type I,
influenced AD) no increase in urinary
cAMP after PTI-I challenge;
cortical adenyl cyclase
present; circulating PTH in-
creased. Type II, urinary
cAMP response intact but
not effective.
Hyperdibasic
aminoaciduria
(12600)
(22270)'
Table 1. Heritable disorders of renal tubular transport in man'
Trait Presumed (or Other Apparent
(McKusick Substance possible) mutant tissues inheritance
cat. No.) affected gene product affected pattern Comment'
Lysine, ornithine
arginine,
("dibasic" group)
Shared "dibasic"
amino acid transport
system (uptake)
Intestine
liver?
brain?
Lysine, ornitbine Shared membrane
arginine and cyst(e)ine efflux system?
Cystine
Hartnup
(23450)'
Intestine
Intestine
(skinfibroblasts
arenormal)
Shared system for
large neutral amino
acid group (uptake)
Proline, hydroxy-
proline, glycinc
Neutral amino acids
(excluding iminoacids
and glycine)
Glutamic aspartic
Taurine, (3-alanine
3-AIB
Glucose
Glucose galactose
Na
(K secondarily?)
Calcium
No primary transport
defect in man; taurinuria
in mouse
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Late proximal or
early distal tubular
mechanism for re-
clamation
Distal tubular collect-
ing duct hydrogen
ion secretion
mechanism
Distal renal tubular H Carbonic anhydrase B Erythrocyte
acidosis with nerve
deafness (26730)2
Idiopathic Fanconi
syndrome
(22770)
(22780)
Symptomatic forms of
Fanconi syndromes:
a) Cystinosis
Type I (2l980)
Type II (2l990)
Type Ill (22000)
b) Hereditary fructose
intolerance
(22960)
XL (dominant) Low Tm1; "negative"
reabsorption of phosphate
can also occur, suggesting
excessive backflux from cell
to urine. Trait responds to
phosphate replacement.
XL (?) Prevalent in males. Low
(recessive) capacity (Tm) for reab-
(or AR?) sorption of HCO3. Daily
requirement of - HCO3 is 10
to l5mEq/kg.
AR (?) "Dislocation" (Km) type
assoc. with hypokalemia &
osteomalacia/rickets.
AD Bicarbonate reclamation
normal. Ability to se-
crete H in distal system
vs. gradient is defective.
Daily requirement of HCO3
is Ito 2 mEq/kg.
AR Progressive nerve deaf-
ness is marker finding.
RTA responds to HCO3-,
Ito 2 mEq/kg.
XL Two alleles (different
(recessive) loci?). Type 1, no urinary
cAMP response to ADH.
? Type II, female proband
urinary cAMP response
intact but not effective.
AR Adult-onset (22780) and
(& AD?) infantile childhood forms
(24270) are differentiated.
Basic defect unknown;
probably several alleles.
AR Several alleles. Infantile
(for each type) (type 1) & adolescent (type
11) forms have differing
rates for onset of nephro-
pathy. "Adult" form (type
Ill) has no nephropathy.
AR Nephropathy dependent on
phosphate depletion in
kidney. Responds to fruc-
tose withdrawal.
c) Galactosemia
(23040)2
Same
(+ galactose)
Galactose- I-phosphate Same
uridyltransferase (with (cataracts, CNS)
secondary effects on
cellular ATP)
AR "Galactosemia" due to
galactokinase deficiency
does not have Fanconi
syndrome. Fanconi syn-
drome responds to galactose
withdrawal.
d) Hereditary
tyrosinemia
(27670)
Same (+ tyrosine
metabolites)
Unknown (with secon- Same (hepatic
dary effects on cellular cirrhosis)
ATP)
AR Fanconi syndrome responds
to tyrosine restriction.
Table 1. (Continued).
Trait
(McKusick Substance
Presumed (or
possible) mutant
Other
tissues
Apparent
inheritance
cat. No.) affected gene product affected pattern Comment2
Intestine?
Bone?
Phosphate carrier
(luminal membrane?)
(retaining cellular
pool)
Proximal tubular
mechanism for
reclamation
Familial hypo-
phosphatemic rickets
(30780)
Renal tubular Bicarbonate
acidosis (type II)
(31240)
Renal tubular acidosis Bicarbonate
(type III)
(26720)
Renal tubular
acidosis (type I)
(l7980)
Intestine
(probable)
Diabetes insipidus
(vasopressin resistant)
(30480)
[-120
Generalized effect on
all solutes & water
Same
(secondary response)
Same
(+ fructose)
Antidiuretic hormone
receptor mechanism
(or messenger system)
Coupling of energy (?) Secondary to
Tight junction integrity renal phenotype
(?)
Cystine storage Same
(lysosomal defect)
with secondary
damage to tubule &
glomerulus (later)
Fructose-I-phosphate Same
aldolase (with secondary (hepatic cirrhosis)
effects on cellular ATP)
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Table 1. (Continued).
f) Lowe's oculocerebro Generalized disfunction Unknown
renal syndrome with defective urinary
(30900) ammonia production
An oculocerebro-
intestinal-renal
syndrome (involving
tissues with high
y-glutamyl cycle
activity?)
XL Basic defect still
(recessive) unknown. Treatment for
tubular reclamation
defects does not improve
mental retardation or the
cataracts & hydro-
phthalmia.
Vitamin D dependency
(pseudodeficiency
rickets) (26470)
Generalized defect. 25-hydroxyvitamin D-
(Secondary response) lo-hydroxylase
(Vitamin D hormone
synthesis occurs in
kidney mitochon-
dna; deficiency af-
fects intestinal
absorbtion of cal-
cium & initiates
PTH response.)
AR Nephropathy dependent on
PTH excess & hypocalcemia
(phenocopy occurs in vita-
min D deficiency.)
Miscellaneous
a) Glucoglycinuria
(13810)
Glucose & glycine Unknown (the two
solutes do not share a
common carrier.
AD Asymptomatic. Normal-Tm
(type-B) glucosuria. Possi-
bility that this is a
heterozygous manifestation
of a Fanconi-like tubulopa-
thy merits consideration.
b) Ludcr-Sheldon
syndrome (15250)
Generalized amino
acids glucose &
phosphate
Unknown AD Same as for previous entry.
Symptoms of Fanconi
syndrome have occurred
in probands.
c) Rowley-Rosenberg Generalized
syndrome (26850) aminoaciduria
Unknown AR Associated components of
syndrome; growth, retarda-
tion, muscular hypoplasia,
pulmonary involvement &
right ventricular hyper-
trophy.
A catalogue of 28 inherited disorders of tubular transport is provided herein. Each disease included in the table has a proven (see footnote
3) or suspected pattern of inheritance and is to be found under its own five-digit catalogue number in the appropriate section (autosomal
dominant, 10,000 series; autosomal recessive, 20,000 series; and X-linked, 30,000 series) of McKusick's Catalogue of Mendelian Inheritance
in Man [161]; selected literature citations are given with each entry. Vignettes covering the major clinical features and the genetic aspects of
many of these traits will also be found in the Compendium of Birth Defects, published by the National Foundation-March of Dimes [1621.
Numerous probable inborn errors of tubular transport are not included in Table I because their tubular manifestations have yet to be
clearly understood. These conditions (and their McKusick catalogue number, if available) include the following: Pyroglutamic aciduria
(26613) due to a defect in glutathioñe synthesis and secondary overproduction of the pyroglutamic acid (5-oxo-proline) intermediate of the
y-glutamyl cycle; idiopathic hypercalcuria (hyperexcretory form) (23810); some patients with Leigh's necrotizing encephalopathy (25600);
Familial nephrosis (25630) with a generalized tubulopathy; and Immerslund's syndrome (26110) with unexplained tubular proteinuria.2 hets = heterozygote, homoz = homozygote.
Proven pattern of inheritance.
acids [6, 32]; nonepithelial cells, such as cultured skin
flbroblasts, do not have the defect [33]. Intestinal
uptake of various dipeptides containing amino acids
affected by the Hartnup trait is not impaired [34—36],
because dipeptides are transported in the gut and
kidney, at membrane sites which are independent of
those used by their constituent free amino acids [37,
38]. Following uptake, dipeptides are cleaved by in-
tracellular peptidases; the free amino acids then enter
metabolic pools or leave the cell. The normal plasma
response curve in the Hartnup trait, following dipep-
tide feeding, indicates that cleavage and absorption of
dipeptide-derived amino acids are normal, therefore,
efflux of the released free amino acids across the
basilar plasma membrane must be intact, and the
defect in transepithelial absorption must be confined
Trait Presumed (or Other Apparent
(McKusick Substance possible) mutant tissues inheritance
cat. No.) affected gene product affected pattern Comment2
e) Wilson's disease Same (with proximal Unknown (seondary 1-lepatolenticular Fanconi syndrome responds
(27790) and distal RTA) effects on cytochrome
oxidase system?)
degeneration to depletion of copper
storage.
AR
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to a specific uptake carrier serving the large
"Hartnup" group of amino acids on the luminal
membrane (viz. Fig. 26—21 in [6]). In the absence of
any comparable studies of dipeptide reabsorption by
kidney, we reason by analogy that a similar location
of the defect in proximal tubule epithelium accounts
for the specific Hartnup hyperaminoaciduria.
Renal glucosuria and glucose-galactose ma!-
absorption. Two autosomal recessive disorders of
hexose transport [39, 40] reveal the likelihood that
renal tubular epithelium possesses two (or more) ge-
netically distinct mechanisms for glucose transport;
this may not be the case in the intestine. The
transport defect in each trait almost certainly in-
volves an uptake system on the luminal membrane.
The characteristics of D-hexose transport in kidney
are complex. Hexose transport mechanisms provide
substrates for the metabolic systems yielding energy
for basal renal work, and also for a component of
renal transport work itself [41]. Hexoses enter prox-
imal tubular cells, in vivo, from luminal and basilar
poles [26, 42]. However, luminal and basilar mem-
branes clearly possess differing characteristics for
hexose transport. By means of the sudden-injection,
multiple-indicator dilution method [26], it has been
shown that there are D-glucose-preferring (G) sites
(shared with D-galactose) and D-mannose-prefer-
ring (M) sites in the luminal membrane [42].
Confirmation of these data, and evidence for Na1-
dependent D-glucose transport at the luminal mem-
brane, has been obtained by a stop-flow micro-
perfusion method [43] and by kinetic analysis
of isolated preparations of brush border membranes
[44]. It is likely also that G sites of luminal and
basilar membranes are not identical [26, 42]. Further-
more, this delineation of hexose transport in the lu-
minal membrane of kidney leads one to believe that
its properties are qualitatively different from those
previously defined for the luminal membrane of in-
testinal epithelium [45].
By means of a technique using isolated, perfused
proximal tubule segments, the characterisitcs for true
transcellular transport of D-glucose have been re-
vealed. D-glucose can be transported against a chem-
ical gradient out of the tubule lumen. Active trans-
port is therefore a property of the luminal membrane.
Glucose reclamation occurs predominantly in the
convoluted portion of the proximal tubule but it also
takes place in the pars recta. The unidirectional fluxes
of D-glucose, from cell to lumen, and from cell to
peritubular fluid, were dissected from the net trans-
epithelial fluxes; outward flux at the basilar pole ex-
ceeds exodus at the luminal border by a four-fold
margin. Basilar permeability to D-glucose is appar-
ently carried-mediated. When the maximum rate of
reabsorption (Tm() is reached, the limiting com-
ponent is, accordingly, uptake at the luminal mem-
brane (or intracellular metabolism), not permeability
at the basilar membrane.
Tubular reabsorption of D-glucose has long been
known to observe a Tm in mammalian kidney in vivo
[46, 47] (Fig. 3). The observed "splay" in the titration
curve relating filtered load to the threshold for gluco-
suria (FminG), and the reabsorption rate, has evinced
much argument. Some consider the observation to be
compatible with ordinary Michaelis-Menten kinetics
for uptake by a single saturable system; others take it
as evidence for anatomical heterogeneity among the
nephrons performing the functions of filtration and
reabsorption [1]. We believe a resolution of this clas-
sical argument among renal physiologists is to be
found in the hereditary disorders of glucose trans-
port.
Reubi [48] observed two variations upon the nor-
mal titration curve in familial renal glucosuria. The
type-A variation is characterized by a low FminG and
low Tm(;; type-B glucosuria has a low FminG but a
normal TmG (Fig. 3). A kinetic interpretation [3, 6,
49] of glucose reabsorption ascribes the type-A vari-
ant to a reduced number of transport sites, while the
type-B variant reflects reduced affinity of the hexose
carrier for glucose. With this in mind, should a hered-
itary disorder of glucose transport involve the in-
testine as well as the kidney, or should the type-A and
type-B phenotypes be found in the same pedigree,
there would then be little room for the nephron heter-
ogeneity hypothesis as an explanation for splay in
solute absorption curves.
When in vivo data for hexose transport are com-
pared with data obtained by the kidney cortex slice
method, additional points of interest are found.
The slice method, which exposes only the basilar
membranes of proximal tubular epithelium to the
incubation medium (see following), reveals active
transport (uptake) of hexoses across these mem-
branes [50. 51]; this finding is analogous to the
evidence for active transport in vivo [19]. The slice
data also reveal more than one type of D-hexose
uptake [48]; this finding is also in keeping with the in
vivo observations [26, 42]. Kleinzeller [49] has delin-
eated a number of homologies between D-hexose
uptake in vitro by kidney slices and during absorption
in vivo. However, Silverman, Aganon and Chinard
[26, 42] have shown with different techniques that
basilar membranes and luminal membranes are not
identical in their hexose carrier properties. Therefore,
the genetic probes of glucose transport in man as-
sume great importance since they may inform us
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about the disposition of hexose carriers in the renal
tubule in a manner not revealed by any previous
study.
Glucose-galactose malabsorption is characterized by
severe impairment of hexose transport in the gut and
minimal deficit in the renal tubule; familial renal
glucosuria is a disorder of renal tubular reclamation
of D-glucose without an intestinal defect.
In glucose-galactose malabsorption, an uptake sys-
tem, which resembles the G-system in kidney brush
border [26, 42], is deleted in the luminal membrane of
intestinal epithelium of homozygotes [40, 52—54]. On
the other hand, renal titration studies reveal little [40]
or no [54, 55] deviation of TmG from normal in
homozygotes (Fig. 3). Endogenous glucose metabo-
lism is normal in the disease [55, 56] and the hexose
transport defect is not expressed in the erythrocytes,
as a representative of nonepithelial tissues [57].
In contrast to these findings in glucose-galactose
malabsorption, there is no aberration of glucose
transport in the intestine of homozygotes with fami-
lial renal glucosuria [58]. However, the renal titration
data reveal a very complex picture compared to the
renal findings in glucose-galactose malabsorption.
(Fig. 3), Studies in three unrelated pedigrees [39, 58]
have revealed a "mild" form of homozygous type-A
glucosuria inherited from "silent" heterozygotes
(COY pedigree, [58]); "severe" type-A glucosuria in-
herited from "mild" type-A glucosuric heterozygotes
(Hold pedigree, [39]) and type-B and "severe" type-A
glucosuria in sibs of a pedigree in which there are
relatives with "mild" type-A glucosuria (Hot ped-
igree, [58]. A compelling argument for at least three
mutant alleles, at a gene locus specifying a renal
glucose transport system, is offered by these observa-
tions. Of particular interest is the evidence that even
Fig. 3. Glucose titration curves showing
maximum transport (reabsorption) rate
(TmG), and venous plasma threshold for
glucosuria (Fmin0), in normal subjects and
in the hereditary glucosurias. Theoretical
type-A and type-B glucosuria titration
curves according to Reubi (1954) are
shown in left panel; note that the hypo-
thetical curves do not conform to the ac-
tual observations in vivo shown in the
three adjacent panels. Actual type-A
glucosuria data (2nd panel from left) were
redrawn from Elsas, Bossy and Rosenberg
[391; type-B glucosuria data (3rd panel
from left) were redrawn from Elsas and
Rosenberg [49]. The data for renal han-
dling of D-glucose in glucose-galactose
malabsorption (right panel) are taken from
Elsas et al (0) [40], Beauvais et al ()
[54] and Abraham et al (A) [55].
"severe" type-A homozygotes retain about one-third
the normal Tm0 (Fig. 3); and that type-B probands
(subject 11-4, Ho!, [58]) have a normal threshold for
glucosuria (FminG) which is about one-third the nor-
mal Tm(.
The combined evidence both from physiologic ob-
servations in several mammalian species [19, 26, 42,
47], and from the genetic studies in man suggests the
following synthesis and hypothesis. Efficient reclama-
tion of hexose by the proximal tubule is controlled by
the luminal membrane. Three types of luminal hexose
carriers operate in parallel in this capacity. One is the
M carrier [26, 42], a diffusional system of no further
interest to us here. The second, which we will call the
G1 system, corresponds to the G-system of Silverman
et al [26, 42]; this carrier interacts with glucose and
galactose and is under control of a gene we will call
the "glucose-galatose" carrier (G1) locus. We pro-
pose that the integrity of the G1 carrier is unmasked
in one condition—severe type-A glucosuria which
causes deletion of a second (G2) glucose carrier.
Evidence for the third carrier, which we call G2, is
revealed in homozygous glucose-galactose malab-
sorption which causes deletion of the G1 carrier and
"unmasks" the activity of the G2 carrier.
We estimate that the maximal capacity of the G1
carrier is about one-third the total capacity for D-
glucose transport in the normal nephron (Fig. 3).
From observations in type-A glucosuria, we deduce
that the affinity of the G1 system for D-glucOSe is less
than that of the principle carrier (G2); this fact is
revealed by the displacen:mt of the titration curve for
the residual glucose transport in homozygous type-A
glucosuria (Fig. 3). The G2 carrier appears to be very
specific for D-glucose and it has a high affinity and
high capacity for D-glucose transport (Fig. 3).
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Mutation at the G1 locus causes glucose-galactose
malabsorption; mutation at the G2 locus causes fami-
lial renal glucosuria. The G2 locus may not be ex-
pressed in the intestine according to physiologic and
genetic evidence; or if there is an intestinal G2 carrier,
it has not been affected by the mutations which per-
mit homozygotes with renal glucosuria to survive and
to be recognized [58]. More than one mutant allele
has already been described for the proposed G2 locus.
One type impairs the capacity of the G2 carrier for D-
glucose and causes "mild" or "severe" Reubi type-A
glucosuria; genetic and phenotypic evidence [40, 58]
implies that there exist two different type-A alleles in
this respect. The other allele alters the affinity of
the 02 carrier for substrate and causes type-B
glucosuria.
Hereditary taurinuria. We divert briefly to discuss
the first of three animal models of hereditary loss of
organic solute. Such examples are rare [3] and, when
they occur, the opportunity they provide for in vitro
investigation is valuable.
We have used the kidney cortex slice method and in
vivo clearance studies, in parallel, to delineate the
location of an inherited impairment of taurine rec-
lamation [59, 60] which has been observed in the
mouse. Taurine is the prevalent 3-amino acid in
mammalian body fluids and it serves as a marker for
a well-documented, 3-amino-acid-preferring trans-
port system in the kidney [38, 60—63].
Wedeen and Weiner have shown that kidney slices
do not necessarily expose proximal tubule luminal
membranes to uptake from the incubation medium
[64-66]. In response, some investigators have been
quick to reject the slice method as a useful technique
to study solute transport in kidney. We have less
reactionary views; we believe the slice method pro-
vides an opportunity to study pools-in-series (Fig. 4)
which can highlight the topology of transepithelial
transport. Quick-freeze, soluble-label autoradiog-
raphy has revealed the distribution of tritium-la-
belIed, inert solutes after their uptake by cortex slices
[64] (Fig. 4, top half). Inulin is confined to an extra-
cellular space in contact witji basilar and lateral
membranes of proximal tubular epithelium; only in
the distal tubule does inulin penetrate the lumen, a-
Aminoisobutyric acid (AIB) is concentrated within
cells of the convoluted and straight portions of prox-
imal tubule, little being found in the lumen; if AIB
fluxes into the luminal pool, it is avidly reclaimed in
vitro, p-Aminohippuric acid (PAH) is accumulated
maximally in the lumen of straight segment but also
in the convoluted portion of proximal tubules. Integ-
rity of the punctate contacts between epithelial cells
at their luminal pole is essential for these solute distri-
butions to occur in kidney cortex slices. Specific, net
flux orientations across the isolated luminal mem-
brane of the proximal tubule are also necessary to
achieve the independent spatial distribution of AIB
and PAH. The findings indicate that the peritubular,
cytoplasmic and luminal pools of proximal tubules in
slices exist in series, and that net reabsorptive and
secretory fluxes across the luminal membrane remain
intact in slices.
The unique topology of slices was put to use in our
study of hereditary taurinuria in the mouse. Taurine
is an inert metabolite in mouse kidney and is there-
fore a useful probe of its transport functions. We
investigated three inbred strains of mice available
from the Jackson Laboratory, Bar Harbor, Maine:
A/J is a normal taurine excretor (taut±) and
C57BL/6J and PRO/Re are two homozygous hyper-
taurinuric strains (taut-). Urine taurine is ten-fold
greater in taut_ animals, while plasma taurine is com-
parable in the three strains. Net tubular reabsorption
of taurine is 96.7 1.3% (mean of the filtered
load in A/J, and 83.9 + 0.8% and 78.7 5.0% in
C57BL/6J and PRO/Re, respectively. Intracellular
taurine concentration in outer cortex in vivo is similar
in the three strains. This important finding, when
interpreted according to the kinetics described in Fig.
1, indicates that backflux from an expanded in-
tracellular pool of taurine is not the cause of hyper-
taurinuria.
Other in vivo findings were of interest. fl-Alanine is
a competitive inhibitor of taurine transport in kidney
[38, 60, 63]. -Alanine inhibits taurine reabsorption
in vivo, in both taut+ and taut_ strains, indicating the
retention of a residual taurine transport activity in
the nephrons of the latter.
Steady-state uptake of taurine at physiologic con-
centrations (about 0.5 mM) by thin, outer-cortex
slices is clearly greater in taut_ than in taut+ tissue.
The higher uptake ratio by taut slices is not the
result of altered efflux at the basilar membrane slice;
efflux from slices is the same in taut+ and taut
strains.
i-Alanine, which shares the taurine transport sys-
tem in vitro [38] and in vivo [60—63], is also taken
up more avidly by taut slices. /-Alanine which is
vigorously oxidized by taut kidney cortex slices [38]
is oxidized less by taut_ slices but normally by slice
homogenates with disrupted architecture.
These data suggest a block in concentrative uptake
of taurine at the luminal membrane of proximal tu-
bule (Fig. 4). l-Taurine is not reclaimed efficiently
from the luminal "lacuna" of slices (the innermost of
the three poo1s in series) once it has fluxed from cell
into lumen. Retention of solute in this pool leads to
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Fig. 4. An interpretation of enhanced taurine uptake as observed in
kidney cortex slices obtained from hyperlaurinuric mice (C57BL/6J
and PRO/Re strains designated taut in text), when compared with
normal mice (A/f, designated taut). Upper half. Figure shows
distribution of 3H-inulin, 3H- (or '4C-) a-amino-isobutyrate (AIB)
and 3H-p-aminohippuric acid (PAl-I) after incubation of rat cor-
tex slices. Inulin does not penetrate the lumen of the proximal
tubule, and is confined to extracellular peritubular and glomerular
spaces; AIB is concentrated by proximal tubule cells. PAH is
maximally concentrated in the lumen of proximal tubule. A con-
cept of "pools-in-series" is implied by these findings (see text).
(Rephotfigraphed from Wedeen and Weiner 163].) Lower half:
Figure shows the enhanced distribution ratio (DR) during time
course for taurine uptake by slices. The. interpretation for this
anomaly is shown in the two sketches at the bottom; it utilizes the
"pools-in-series" hypothesis. The shaded area indicates the inulin
space; the adjacent clear area is the cytoplasmic pool; the luminal
pool is drawn at the apex bounded by luminal membrane and tight
junctions (shown by solid bars). The luminal pool can be entered
from the extracellular space only through the cytoplasm. Taurine
becomes trapped in the luminal pool (stippled area) of taut_ slices.
Four relevant permeation fluxes are shown: influx across basilar
membrane (J1); efflux into luminal pool (J2); reclamation flux from
luminal pool (J3); and efflux across basilar membrane (J4). J3
exceeds J2 under normal conditions so that little amino acid is
retained in the luminal pool. Assuming J3 = [Tau1J X
permeability1,, where Ic is the lumen-to-cell movement, accumula-
tion of taurine in luminal pool will occur if luminal membrane
permeability1, is decreased, all other events being unchanged. The
change in J3 in taut_ kidney is presumed to be the result of an
hereditary impairment of transport at the urinary surface of the
taurine carrier in the luminal membrane (from Chesney RW, Scri-
ver CR, Mohyuddin F, J. Cnn Invest, vol. 57, 1976, in press).
the higher uptake ratio observed in vitro. The in vivo
data indicate "sequestration" of taurine in the urine
pool, a finding also compatible with a luminal mem-
brane transport defect. In vitro and in vivo data are
thus concordant. We believe that in vivo and in vitro
data have been used in parallel, in this case, for
topological assignment of a hereditary transport de-
fect to a specific membrane surface in the mamma-
lian nephron. Appropriate studies—both with quick-
freeze, soluble-label autoradiography to discern
whether labelled taurine accumulates in excess in the
lumen of taut- slices, and with isolated brush border
membranes to study taurine binding—will either af-
firm or dispute these conclusions.
lB. Defects in the integrity of the (luminal) plasma
membrane to efflux. No hereditary disorder of tubular
transport has been proven in this class. However,
there is precedent for genetic control of exodus in
prokaryocytes [67, 68]; and two disorders in man are
reasonable candidates for this type of defect.
Wong, Kashket and Wilson [671 describe a genetic
defect of thiogalactoside transport in Escherichia coli,
and Hectman and Scriver [68] found a mutant strain
of Pseudomonasfluorescens defective in -alanine ac-
cumulation. Both mutants are unable to concentrate
the relevant free solute against a gradient in the in-
tracellular pool, yet both retain the pertinent carrier
in their plasma membranes. It was surmized in both
that the mutant carrier was unable to prevent solute
efflux following uptake into the intracellular pool.
With these precedents in mind, it has been proposed
[69, 70] that classical cystinuria and X-linked hypo-
phosphaturia may be disorders in which the relevant,
specific carriers in the luminal membrane are mutant
so as to allow abnormal backflux, while still retaining
their carrier functions for facilitated entry.
Cystinuria is an autosomal recessive disorder char-
acterized by defective transport of the diamino dicar-
boxylic amino acid cystine, and the diamino mon-
ocarboxylic amino acids lysine, ornithine and
arginine [71]. Two or more mutant alleles exist at the
gene locus controlling the transport function in-
volved in cystinuria [72]. Net tubular reabsorption of
the four amino acids is greatly impaired in mutant
homozygotes and in "genetic compounds". It is par-
tially impaired in heterozygotes for two of the three
proposed alleles [72].
While FminLYS and TmLYS may both be zero in
homozygous cystinuria, Lester and Cusworth [73]
have shown that lysine infusion will still provoke
enhanced excretion of ornithine, arginine and cystine.
They, and others [74, 75], have also shown that the
endogenous renal clearance of cystine and the other
affected amino acids can exceed the clearance of in-
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ulin, so that the "negative reabsorption"3 of amino
acids occurs in cystinuria. On the other hand,
cyst(e)ine uptake is only slightly depressed, if at all, in
slices prepared from human cystinuric kidney [72, 76,
77, 78]; the representative dibasic amino acid lysine
observes a reduced rate of uptake without change in
its apparent Km for uptake [72, 76, 78]. The carrier
retains its ability to interact with the dibasic amino
acids. By contrast with these findings in kidney, the
uptake of both cystine and the dibasic amino acids is
clearly impaired in the intestine in homozygous cys-
tinuria [721.
The original hypothesis of Dent and Rose [79], and
of Robson and Rose [80], stated that cystinuria is a
defect in a selective transport (uptake) system of the
tubule shared by cystine and the dibasic amino acids.
However, subsequent work in vitro has shown that
cystine and the dibasic amino acids do not share a
common system for uptake across the basilar plasma
membrane of the tubule as it is exposed in slices of
mammalian kidney [60, 81, 82]. On the other hand,
cystine, cysteine and the three dibasic amino acids all
interact with each other at the luminal membrane, in
the normal proximal tubule, presumably on a shared
site [83]. The discordance between the properties of
uptake sites on luminal and anti-luminal membranes
is further ramified when efflux is considered.
Schwartzman, Blair and Segal [84, 851 showed that
cysteine and the dibasic amino acids shared a mem-
brane efflux site in kidney cortex slices. The
properties of the efflux system appear not to be dupli-
cated completely at the corresponding influx site; nor
does the efflux carrier experience the customary prop-
erties of counterfiow. These properties might be ac-
comodated by the behavior of carriers on the outer
surfaces of luminal and basilar membranes when ex-
posed in the slice model (see above, hereditary tauri-
nuria discussion) except for the following facts.
We know also that a mixed disulfide (cysteine-
homocysteine) is prominent in cystinuric urine [86];
that the renal arterial:venous extraction ratio is nor-
mal for cysteine, and for cystine, in cystinuria [87];
and that the intracellular cysteine:cystine ratio in nor-
mal human and cystinuric renal cortex is normally
about 10: 1, regardless of the form in which cyst(e)ine
The term "negative reabsorption" is sometimes used when it is
found that the excretion rate (UV) of a solute exceeds its load in
glomerular filtrate (F), whereas the customary relationship is F >
uv. The term "net secretion' could also be used in this instance
provided it was not implied that UV > F was the result of a
specific energy-dependent secretion process. When used in this
paper, negative reabsorption implies an abnormal finding;
secretion is reserved for normal functions in which UV > F is the
customary relationship.
enters the cell [77, 88]. Each of these latter
observations suggests that intracellular cysteine is the
source of excess urinary disulfide in cystinuria.
These disparate observations at first defy coherent
interpretation. Moreover, the genetic evidence (Table
I) tells us that mutation, in the form of isolated
hypercystinuria, and as hyperdibasicaminoaciduria,
can impair tubular reabsorption of cystine and the
dibasic amino acid quite independently, a finding
which is explicable only if we assume that the luminal
membrane contains reactive sites which are
cyst(e)ine-specific and dibasic amino acid-specific,
each under the control of separate genes. However, to
reiterate, the physiological evidence [83] tells us that
a third species of uptake site in the luminal
membrane of the mammalian nephron is shared by
the five naturally occurring amino acids, but that this
site is apparently not present in the basilar membrane
[61, 81, 82]. Loss of only the luminal membrane
system [83] (shared by cysteine, cystine, lysine, orni-
thine and arginine) would indeed account for the
cystinuria trait as we know it. But this simple inter-
pretation would not explain the stimultaneous obser-
vation of zero FminLYS, zero TmLYS, negative reab-
sorption of amino acids and competitive interaction
between the four amino acids during reabsorption.
An alternative and seemingly unifying interpretation
is to propose that cystinuria is a defect in a shared
effiux system of the plasma membrane so that the
relevant intracellular amino acids (cysteine, lysine,
ornithine and arginine) experience exaggerated
exodus. This interpretation explains most of the in
vitro data and would account for backflux into urine
from the intracellular pool to yield negative reabsorp-
tion under certain conditions. The relevant amino
acids still interact on a shared luminal membrane
uptake system which permits competitive inhibition
to occur under certain conditions.
The second candidate for defective luminal efflux is
X-linked hypophosphatemia (familial hypophospha-
temic rickets). In this "phosphopenic" form of rick-
ets [70] tubular reabsorption of phosphate is selec-
tively affected [891; a corresponding defect in
intestinal absorption may also exist [901. The vener-
able hypothesis of Albright ascribed the defect in
tubular reabsorption of phosphate in familial hypo-
phosphatemia as a consequence of secondary hy-
perparathyroidism initiated by a primary disorder of
vitamin D-dependent calcium absorption in the in-
testine [911. However, this is implausible as there are
no elevated serum concentrations of C-terminal im-
munoreactive PTI-I in mutant hemizygotes unless cal-
cium homeostasis has been altered [70]. Moreover,
the anticipated generalized defect in tubular reab-
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sorption of solute which accompanies "calciopenic"
secondary hyperparathyroidism [70] is not observed
in the X-linked trait. Furthermore, normal urinary
cyclic-AMP excretion under basal conditions [89, 92]
is partial evidence against the defect being a selective
hyperresponsiveness of the tubule to normal levels of
circulating PTH [93]. Mutant hemizygotes also mani-
fest a low Tm1 and negative reabsorption of ortho-
phosphate [89, 92, 94]; these two findings focus
interest on a primary transport defect involving
orthophosphate.
The fortunate discovery by Eicher and Southard,
at the Jackson Laboratory, of an X-linked mutation
which causes hypophosphatemic rickets in the mouse
has allowed us to investigate, in preliminary fashion,
the mechanism of hyperphosphaturia in this pre-
sumed model of the human disease. Renal tubular
reclamation of orthophosphate is equally diminished
in the mutant mouse and in man. Concentrative up-
take of phosphate by cortical and medullary slices
appears to be normal in the mutant hemizygous
mouse; and the intracellular concentration of total
and inorganic phosphate also appears to be normal
[95].
A hypothesis is proposed to accomodate the find-
ings in X-linked hypophosphatemia. We suggest that
the mutation permits excessive luminal efflux (back-
flux) of cytoplasmic phosphate ion to account for
negative reabsorption in the trait. We also suggest
that the equilibrium of phosphate between four pools
in series may determine its net transepithelial flux; the
luminal, cytoplasmic, mitochondrial and peritubular
spaces comprise the four phosphate pools. Partition
of phosphate in the mitochondrial pool may be found
to be important in the transepithelial movement of
phosphorus, modulating it in a manner analogous to
that proposed for transepithelial movement of cal-
cium [96]. The hypothesis requires us to know
whether concentration of phosphate in the cytoplasm
available to backflux is dependent to any extent on
the amount in the mitochondrial pool. It may be of
significance that mitochondria, particularly of prox-
imal tubule cells, are palisaded at the basilar mem-
brane [7], forming an interface between peritubular
and cytoplasmic pools. Events which diminish or in-
crease phosphate activity in mitochondria may come
to influence phosphate activity in cytoplasm in a
series model of transport and may help to explain the
various effects of calcium and PTH infusions re-
ported in X-linked hypophosphatemia [89, 92, 93].
It is implied that a disorder of luminal membrane
backflux could be expressed in any portion of neph-
ron and could come to influence net reabsorption in
both the proximal and distal tubules. Any test of the
luminal membrane effiux hypothesis, in cystinuria
and X-linked hypophosphatemia for example, should
consider this possibility.
2. Disorders of intracellular pool size. Interference
with metabolic disposal ("run out") of solute could
lead to expansion of the intracellular pool in the
presence of continuing uptake (Fig. 2). Conse-
quently, the effective concentration of solute which
interacts with the luminal carrier at the intracel-
lular interface could increase; under this condi-
tion, backflux into the lumen and the moving column
of urine must increase, all other events being equal, as
the efflux component at the luminal membrane re-
sponds to the elevated, internal solute concentration
(Fig. 1). In this respect, intracellular metabolism of
solute comes to influence its transtubular migration.
One cannot avoid thinking of the possibility, that
under this circumstance the Tm of a solute may be
influenced by its renal metabolism [97, 98].
Renal tubular reabsorption of amino acids has
been carefully measured in phenylketonuria and sar-
cosinemia, two blocked-catabolic mutant states in
man, to determine whether impaired catabolism of
the solute impedes its reabsorption [99—102]. In
phenylketonuria the hepatic conversion of phenylala-
nine to tyrosine is almost completely blocked [103].
Phenylalanine hydroxylase activity, with about one-
fifth the specific activity of the hepatic enzyme, is
found in human renal cortex [104]. However, it is not
known whether the renal enzyme is an isozyme or
whether it is deficient in phenylketonuria. It is known
from measurement of phenylalanine reclamation that
there is no abnormality of tubular reabsorption of
this amino acid in phenylketonuria [99, 100, 101].
A similar observation has been made for sarcosine
reabsorption in sarcosinemia [102]. It is likely that
less than 10% of total body sarcosine oxidation takes
place in mammalian kidney [102, 105]; a severe loss
of sarcosine oxidation in one of our patients was not
accompanied by impaired renal reabsorption of this
amino acid [102], indicating that renal oxidation of
this amino acid is unimportant in its reabsorption.
Accumulation of sarcosine in the mutant state ac-
tually enhances glycine reabsorption [102] even
though sarcosine and glycine interact competitively
on their shared uptake sites [6, 102]. Counterfiow
between the raised intracellular sarcosine and urinary
glycine on the luminal carrier appears to be a satisfac-
tory explanation for the behavior of glycine reabsorp-
tion in sarcosinemia. The latter finding also suggests
a normal backflux exchange activity at the luminal
membrane in sarcosinuric kidney and no loss of car-
rier integrity, It follows from the examples of phenyl-
ketonuria and sarcosinemia that an initial increase in
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the amount of an amino acid in its peritubular and
luminal pools does not come to influence the capacity
for its net tubular reabsorption, beyond the normal
kinetics of concentration-dependent uptake [13] at
the plasma membrane.
Another animal model (the third and last to be
mentioned in this review) has provided a valuable
opportunity to examine directly the effect on net
tubular absorption of an initial increase in
intracellular pool size [97]. The mutant homozygous
PRO/Re mouse has hyperprolinemia and less than 1%
of the normal proline oxidase activity in kidney [106,
107]. Under normal conditions, proline is reclaimed
avidly from urine by the mammalian nephron [61,
108, 109]; the kidney also takes up proline from pen-
tubular plasma in vivo [110]. In the PRO/Re mouse,
the endogenous proline concentration is eight times
normal in plasma and four times normal in kidney
cortex; by contrast it is fifty times normal in the urine
[97]. The in vivo, steady-state uptake of proline across
the basilar plasma membrane is not impaired and
efflux at this surface is normal; the integrity of the
well-documented proline transport systems in these
membranes [Ill, 112] is also retained in PRO/Re
kidney. Appropriate studies also reveal the luminal
membrane uptake of proline to be intact in the
PRO/Re mouse [97].
Proline oxidation in normal mouse kidney is of
such large capacity that the intracellular proline pool
is kept at a low level [97]; consequently, the normal
metabolic outflow comes to influence proline uptake
rather dramatically. Normal slices do not observe
any expansion of the soluble proline pool until the
external substrate concentration is greatly elevated;
and saturation of tubular reabsorption in vivo (Tmpro)
is not observed in the normal mouse until the filtered
proline load is augmented far beyond the limit which
is required to delineate the Tmpr in man.
The extraordinary hyperprolinuria which charac-
terizes the PRO/Re mouse can be understood only
by taking into account the elevated intracellular con-
centration of free proline [97]. When we apply Mi-
chaelis kinetics (Fig. 1), we see excessive prolinuria in
the PRO/Re phenotype as a simple consequence of
the primary elevation in the concentration of in-
tracellular proline in vivo (depicted as Sib in Fig. 1).
Efflux of proline is thus enhanced on the same normal
carrier that moves it normally into the cell either from
urine, or from peritubular fluid. However, when
exodus occurs across the luminal membrane, proline
will emerge into a moving column of fluid; since its
distal tubular reclamation is insignificant [6], the
"lost" proline will appear in bladder urine. Fractional
excretion of proline is accordingly elevated in the
PRO/Re mutant. The in vivo topology of trans-
epithelial transport permits this phenomenon to be
observed in PRO/Re kidney whereas the in vitro
topology does not.
With the hindsight afforded by the PRO/Re
model, it is of interest that the venous plasma thresh-
old (FminPRO) for prolinunia in some human ho-
mozygotes with autosomal recessive hyperprolinemia
appears to be slightly lower than the threshold ob-
served in normal persons [108]. That finding suggests
that renal proline oxidase activity may subtly in-
fluence proline reabsorption even in man. It is also
apparent from these observations that the classical
Tm concept will require reevaluation since renal
metabolism of a solute does indeed influence its rate
of tubular absorption.
3. Disorders of exodus at the antilurninal pole. This
type of disorder would impede net transtubular mi-
gration of solute (Fig. 3). The result would be en-
hanced intracellular accumulation of the substrate
leading to exaggerated backflux at the luminal sur-
face. Thus far, only experimental models of this
mechanism have been reported.
The rapid-injection, multiple-indicator dilution
technique has shown [10, 42, 113] that most solutes
which interact competitively to augment their frac-
tional excretion do so at the luminal membrane.
However, an equivalent competition between solutes
during unidirectional exodus at the basilar plasma
membrane [84, 85] could also impede net
reabsorption. The effect of artificially blocked exodus
on fractional excretion has been studied in the ligated
ureter preparation in vivo [31, 114]. L-Arginine en-
hances renal clearance of L-lysine in the ligated dog
[31] in part by causing the intracellular lysine concen-
tration to increase through competitive interaction
between lysine and arginine at the efflux site in the
basilar membranes. Corresponding experiments in
the rat [114] showed that L-lysine provokes cellular
accumulation of S-labelled products derived from
extracellular L-35 S cystine, and increases the renal
clearance of L-cystine. These findings illustrate the
general theme of this review, that renal uptake and
transtubular migration are independent phenomena
[115]; they also support the likelihood that blocked
efflux of solute from the basilar pole of the epithelial
cell can impede net reabsorption. It remains for in-
vestigators to find a disease of tubular function in
man which fits this interpretation.
Generalized disorders of tubular transport
The renal Fanconi syndrome [116] of various eti-
ologies, and the X-linked, oculo-cerebro-renal syn-
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drome of Lowe, Terry and MacLachlan [117] are ex-
amples of generalized disruptions of tubular
transport activities.
The Fanconi syndrome can be defined as the in-
tegrated clinical manifestations, of whatever cause,
resulting from excessive urinary loss of three or more
classes of solutes including the amino acids, mono-
saccharides, electrolytes (phosphate, calcium, bi-
carbonate, potassium, sodium), uric acid and protein
(particularly /3-globulins); water loss also occurs.
Substances not normally observed in any quantity in
urine may also appear in excess, including lithium,
magnesium, insulin and vitamin D and even ly-
sozyme [118]. The increase in fractional excretion of
these solutes is largely due to reduced net tubular
reclamation. However, impairment of tubular secre-
tion is also observed in the syndrome; for example,
TmPAH is depressed [119].
Morphologic abnormalities may accompany the
Fanconi syndrome. The swan-neck lesion, which in-
volves the initial portion of the proximal tubule, is a
hallmark [120]. In all likelihood, this lesion is second-
ary to the underlying cause of the syndrome. The
atrophy of the absorptive surface in the anatomial
lesion further reduces the membrane activity avail-
able for transport. Many species of transport sites are
nonetheless still active, in the atrophied epithelium,
since the normal competitive interactions between
molecules, which share reactive sites, are retained in
the Fanconi syndrome [79, 121] (Fig. 5).
A reduced Tm value characterizes the tubular
transport of various solutes in the Fanconi syndrome
(Fig. 5). This finding alone could be attributed to a
simple reduction in the activity or the number of
carriers in the membrane (equationl). However,
negative reabsorption has also been observed at high
plasma solute concentrations in some patients with
the syndrome (Fig. 5) and this finding implies more
than the loss of carrier activity. The work of
Bergeron, Vadeboncoeur and Laporte with the ma-
leic acid model of the Fanconi syndrome [25, 122,
123] is of particular interest in the latter context.
Maleic acid is a noncompetitive inhibitor of solute
uptake by kidney in vitro [1251, and it causes the
Fanconi syndrome in vivo [1241. Within a few hours
of exposure to sodium maleate (400 mg/kg i.p.),
there is a profound deterioration in the network of
perimitochondrial membranes [123]; this anatomical
abnormality and the Fanconi syndrome appear and
then abate in parallel after the maleate injection.
Following peritubular capillary injection of leucine in
the maleate-treated rat, the amino acid appears in
tubular urine at a rate indicating direct transtubular
flux [25]. There is also a reduction in the cellular
Fig. 5. Upper part: Renal titration curves relating proline reabsorp-
tion to filtered load in normal subjects and three patients with tije
idiopathic Fanconi syndrome. The lower normal range for Tmpao
1109] is shown by the shaded area. Reabsorption is depressed at all
concentrations of proline in ultrafiltrate in the Fanconi syndrome.
In two subjects, excreted proline exceeded the filtered load when
the plasma proline concentration was raised indicating "negative"
reabsorption under these conditions. Lower part: Proline inhibits
glycine competitively on a shared, high-capacity system for uptake in
the normal subject /109, 111/. The upper normal range for frac-
tional excretion of glycine in the presence of proline is shown by
the shaded area. Glycine excretion is abnormally increased, even at
normal endogenous levels of proline in the Fanconi syndrome,
indicating excessive inhibiton of reclamation, or excessive back-
flux, of glycine on its tubular transport systems [109, 111]. The
response to proline inhibition is unusual in two subjects and nega-
tive reabsorption occurred. The latter finding indicates retention of
membrane sites at which counter-flow inhibiton of uptake may be
occurring simultaneously. Negative reabsorption of other amino
acids was not observed indicating a selective interaction between
proline and glycine at a site whose ability to retain solute has been
compromised in the Fanconi syndrome.
concentration of the amino acid while its fractional
excretion is elevated [122]. Exaggeration of these
findings to the point of "negative reabsorption" can
be imagined.
"Negative reabsorption" in the human Fanconi
syndrome (Fig. 5) and transtubular backflux of solute
with reduced cellular accumulation in the maleic acid
model in the rat suggest that two fundamental mech-
anisms are potentially adrift in the syndrome. The
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defect in tubular transport may encompass enhanced
exodus at the luminal surface after uptake of solute at
either pole (see' defect lA, Fig. 2). The mechanism
may be a loss of dynamic asymmetry in the carrier
secondary to a disorder of energy metabolism and its
coupling to the carriers. The other defect concerns
integrity of punctate contacts between cells; integrity
is maintained by a variety of factors including cellular
metabolism.
Hereditary fructose intolerance (HFI) [126] is a
disease which illustrates how metabolism can be com-
promised in the Fanconi syndrome. The metabolic
abnormality induced by fructose in HF! is initiated
by cellular storage of fructose-i-phosphate (F1P) in
liver, kidney and bowel [126]. The Fanconi syndrome
accompanies this metabolic event [127] waxing and
waning with exposure to and withdrawal of D-fruc-
tose in the diet. Tissues normally assimilate fructose
and vigorously convert it to glucose and lactate.
Fructokinase catalyzes the phosphorylation of fruc-
tose to F1P; disposal of F1P requires fructose-l-
phosphate aldolase which is present in splanchnic
tissues and muscle, The aldolase (B-isoenzyme) of
splanchnic tissues has strong cleavage activity toward
F1P and strong condensing activity toward
dihydroxyacetone phosphate and D-glyceraldehyde
phosphate [129]. HF! is characterized by deficient
aldolase-B activity.
The critical enzymes required for fructose metabo-
lism in human kidney are found in the cortex but not
in medulla [128]. This finding constitutes strong in-
direct evidence that renal cortex metabolizes fructose
by the FIP route, and that storage of FTP would
occur in this region of kidney in HF!. The association
of a precise anatomical location of fructose
metabolism in kidney, and provocation of the Fan-
coni syndrome by exposure to fructose in HFI, is
intriguing. The normal activity of fructokinase per-
mits large amount of FiPto accumulate in HF! upon
exposure to fructose. This response is accompanied
by a fall in serum inorganic phosphorus while cellular
adenosine triphosphate (ATP) is consumed to form
the F1P [129]. This relationship in HF! constitutes a
"futile" hydrolysis of ATP, with depletion of high-
energy phosphate and inorganic phosphate pools arid
it is analogous to the situation in galactosemia in
which the Fanconi syndrome also occurs [130].
Parathyroid hormone plays an important modu-
lating role in the pathogenesis of the Fanconi syn-
drome in HFI [131]. Administration of D-fructose
may not provoke the Fanconi syndrome in the ab-
sence of the hormone [131]. Parathyroid hormone
stimulates renal adenyl cyclase and ATP consump-
tion. The "threshold" defect in ATP metabolism,
which appears to exist in HFI, highlights the energy
requirements of mechanisms serving transtubular
transport. From this perspective it is worth recall-
ing that solutes of different species which do not
share common carriers in kidney membranes can still
impede each others' reabsorption [132] or uptake[133] by mechanisms which do not involve
competitive interaction [133]. Competition for avail-
able energy may occur under such circumstances, a
mechanism which may explain the unusually intense
inhibition of amino acid reabsorption upon exposure
to solute loads in the Fanconi syndrome (Fig. 5).
Disorders of net tubular secretion
There is no known primary hereditary disorder
affecting the active tubular secretion of organic so-
lutes, with the possible exception of some forms of
hyperuricemia. However, one can speculate that or-
ganic anions which escape excretion by nonionic dif-
fusion [134], and which require conjugated transport
systems for their tubular excretion, are eligible sub-
strates for inborn errors of tubular transport. The
recent finding that the proximal tubule contains li-
gandin [135], an organic anion-binding protein which
is antigenically similar to the hepatic Y protein, yields
a candidate for an organic anion carrier in kidney.
An inherited deficiency of ligandin would provide a
significant test of its importance in tubular secretion
of organic anions. In the meantime, we can question
whether ontogeny of renal ligandin activity, similar
to that of hepatic Y protein [136], is an explanation
for the abnormally low secretion of substances such
as PAH, chloramphenicol and penicillin in the hu-
man newborn. An alteration in ligandin-dependent
organic acid excretion might even explain why a por-
tion of gouty individuals with normal uric acid pro-
duction have reduced net renal urate clearance with
resultant hyperuricemia [137]. Finally, if it is an im-
portant organic anion carrier, we could understand
better why hyperuricemia occurs in type-I gly-
cogenosis, diabetes mellitus, lactic acidosis, maple
syrup urine disease and fructose-i ,6-diphosphatase
deficiency when there is endogenous accumulation of
the organic acids peculiar to each of these conditions
[133].
Inherited defects of distal tubular acidification are
likely to represent true disorders of net tubular secre-
tion. Classical renal tubular acidosis (type I or cRTA)
occurs when the normal hydrogen ion gradient be-
tween tubular urine and plasma is not maintained.
Accordingly, there is an inability to lower the urine
pH no matter how marked the systemic acidosis
[139]. Three abnormalities of hydrogen ion secre-
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tion could occur: 1) H secretion may be normal but
with excessive back diffusion, so that the normal H
gradient (800: 1-1000:1) between urine and plasma is
dissipated; 2) H secretion may be normal but only
up to a limited capacity, above which no further
acidification can occur; 3) H secretion may be de-
creased at any urine pH. Recently findings suggest
that the third mechanism is an attractive explanation
of cRTA [140]. Long ago, Pitts and Lotspeich [141]
postulated that the elevated urinary Pco2 in alkaline
urine, which is generally 35 mm Hg higher than in
plasma, is the result of distal H ion secretion fol-
lowed by delayed, noncatalyzed, dehydration of
HZCO3 to form CO2 and H2. The gradient between
urine and plasma was assumed to be dependent on
impermeability of the collecting duct to C020. Pak
Poy and Wrong [142] were the first to observe that
the normal Pco2 gradient was absent in patients with
distal RTA. This finding was extended by Halperin et
al [140] who examined the urinary Pco2 gradient
after loading their patients with bicarbonate to max-
imize H secretion. In their opinion [140] the most
tenable explanation for the negligible Pco2 gradient
which they found is deficient H secretion, without
production of carbonic acid for delayed dehydration
to CO2. Others [143] have provided counter-evidence
to this hypothesis, and suggest that the low urinary
Pco2 in cRTA may represent excessive backflux of
H2C03 in alkalosis, and of H during acidosis.
Absence of erythrocyte carbonic anhydrase B has
been described in a family with distal RTA and deaf-
ness [144]. This observation is intriguing, in view of
the suggestion of Maren [145] that distal bicarbonate
reclamation is entirely dependent on intracellular
carbonic anhydrase activity, which provides H ions
to combine with HC02. Distal tubular carbonic anhy-
drase has not yet been shown to be abnormal in these
patients.
Disorders accompanied by altered
tubule-hormone interaction
Hormones regulate several tubular transport func-
tions. Such transport activities will be modified if the
tubule is hyperresponsive to normal (or elevated)
serum concentrations of the relevant hormone; or if
the tubule receptor and translation system are unre-
sponsive to the normal regulatory action of the hor-
mone. Both phenomena can be illustrated by inher-
ited disorders which involve parathyroid hormone
(PTH). PTH-responsive, membrane-dependent activ-
ities appear to be localized to the basilar surface of
outer cortical tubule segments [146].
Autosomal recessive vitamin D dependency
(ARVDD) [70] is a disorder in which the renal syn-
thesis of la, 25-dihydroxycholecalciferol, a hormonal
form of vitamin D, is apparently defective. A "calcio-
penic" form [70] of postnatal rickets develops, ac-
companied by secondary hyperparathyroidism; a
generalized defect in proximal tubular transport
follows. All abnormalities disappear when phar-
macologic doses of vitamin D, or quasi-physio-
logic doses of la-hydroxyvitamin D analogues, are
given. The disorder of tubular transport in ARVDD
is related, in some manner, to the constellation of
vitamin D hormone and calcium depletion and of
PTH excess. Depression of extracellular calcium ion
[147] or elevation of cytoplasmic calcium [148] in-
creases plasma membrane permeability. Calciotropic
hormones which can modify cytoplasmic calcium al-
ter tubular transport of amino acids and other solutes
[149]. Depression of cytoplasmic calcium also in-
creases tight-junction permeability [150]. Depression
of cytoplasmic calcium is likely to occur in ARVDD,
the result being a change in membrane and
transtubular permeability, so that reclamation of so-
lute may be depressed or backflux enhanced. It is also
apparent from recent work [96] that the excess of
PTH and the depletion of vitamin D hormone, which
characterized ARVDD, will combine to deplete mito-
chondrial and cellular calcium and further alter cal-
cium-dependent cellular permeability.
Pseudohypoparathyroidism of the classical type
(PHP, type I) is an example of tubular unrespon-
siveness to PTH. In this disease, there is a fail-
ure of PTH infusion to augment urinary cyclic 3',
5'-adenosine monophosphate (AMP) [151] and frac-
tional excretion of phosphate is diminished. Endo-
genous serum PTH levels are typically elevated while
serum calcium remains low and phosphorus is ele-
vated. Recent studies [152] have shown that the PTH
receptor and adenyl cyclase in renal cortex are appar-
ently intact in PHP-type 1; it is the mechanism of
cellular response to PTH and the effect on solute
transport which are defective. On the other hand,
cyclic AMP-dependent mechanisms in the tubules
responsive to hormones other than PTH seem to be
intact although this facet of the problem has not been
rigorously examined to our knowledge. It is of inter-
est that the renal adenyl cyclases responsive to PTH,
calcitonin and vasopressin are preferentially located
in outer cortex, inner cortex and medulla, respec-
tively [146]. The basis for the insensitivity of adenyl
cyclase to PTH in the intact tubule in PTH-type I
remains obscure.
A variant of PUP known as type II PHP, has been
reported [153, 154]. In this trait, fractional excretion
of phosphate remains insensitive to PTH infusion,
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but a brisk increase in urinary cyclic AMP testifies to
a responsive renal adenyl cyclase. PHP type II is
further distinguished by a normal serum concen-
tration of inorganic phosphate, a feature which
remains unexplained at present. Many facets of the
tubular metabolism and handling of vitamin D, phos-
phate and calcium, as well as of cyclic AMP
metabolism regulated by PTH, are pertinent to the
interpretation of PHP, but are beyond the scope of
this review.
Commentary
In this review we have used some of the inborn
errors of tubular transport listed in Table 1 to illus-
trate, in a specific manner, the various components of
transtubular movement of solute. These experiments
of nature, as well as the steadily increasing body of
laboratory experimentation in man and animals, sup-
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Fig. 6. Renal clearance studies in the rat after bolus injection of 1'C-
labelled x-amino-isobutyrate (AIB), an inert synthetic amino acid.
Fractional excretion (left ordinate) rises above the 15-mm value
(set at zero to accommodate interindividual variation between 0.03
and 0.05 at 15 mm), to approach a steady state after 90 mm while
the plasma concentration of A1B is falling (.—., (right ordinate).
3H-inulin clearance remained stable during the experiment. The
reciprocal fall in fractional reabsorption of AIB with time could
reflect saturation of an intrarenal binding process; this explanation
is unlikely since reinjection of AIB, or elevation of MB plasma
concentration, did not alter the phenomenon. AIB equilibration
between peritubular fluid and epithelium followed by backflux into
the lumen is a more likely explanation. AIB concentration fell in
the cortex between 30 and 195 mm (from 1284 + 25 cpm/mg of wet
wt of prepared slice, mean SD [N = 161 to 953 + 26cpm/mg[9N
= 16], whereas the concentration remained unchanged in medulla
(from 830 + 218 cpm/mg [N = 8] to 923 274 cpm/mg [N = 8]).
When considered with the plasma AIB levels, these figures indicate
that although the distribution ratio of AIB is the same in Cortex and
medulla at 3'/2 hr, it is significantly less in the medulla than the
cortex at 30 mm. These tissue changes were not an artefact of
changing urine or plasma AIB concentration. The findings suggest
that a slowly accumulating tissue poo1 of AIB in the medullary
portion of the nephron is a potential source for enhanced luminal
exodus (backflux) and, thus, of the observed increase in fractional
excretion (Mclnnes RR, Scriber CR, unpublished data, [149]).
port what others have proposed recently [31, 97, 114,
115]; that accumulation of solute by renal tubule cells
and its transtubular transport are each essentially
different processes, the former being most evident in
the straight protion, the latter in the convoluted por-
tion of proximal tubule [115]. The normal topology
of absorbing epithelium provides the framework for
these concepts which, being of fairly recent origin, are
still likely to be a source of controversy as well as a
stimulus for further investigation. On the other hand,
if they are valid, it should not be surprising that
tissues lacking the topological orientations of epithe-
hum (e.g., erythrocytes, blood leukocytes and cul-
tured skin fibroblasts) fail to show any abnormality
of solute transport wherever the investigation has
been performed, as in cystinuria [155], Hartnup dis-
ease [33], iminoglycinuria [156], glucose-galactose
malabsorption [57] and X-linked hypophosphatemia
[157], for example.
Various elegant experimental methods have pro-
vided the important evidence for normal backflux
across the luminal membrane, transtubular fluxes in
both directions and differential handling of solute
uptake and migration in different regions of the kid-
ney (e.g., [19,, 25, 31, 83, 114, 115].) Even the
traditional "black box" clearance method appears to
honor this theme (Fig. 6). As a result of this new
awareness, our interpretation of altered Tm values,
fractional reabsorbtion rates relative to solute con-
centration and other clinical indices of altered net
tubular transport in the inborn errors of tubular
function is likely to undergo refinement in the future.
All of this will benefit diagnosis, counselling and
treatment of patients with hereditary disorders of
tubular transport.
The expression of mutant alleles which affect the
gene products controlling the various stages of trans-
tubular transport is also complex [3, 61. The gene loci
which determine the structure and quantity of the
relevant proteins are likely to exhibit one or more
mutant alleles per inborn error of transport. Genetic
heterogeneity underlies a great many monogenic dis-
eases [158] and the hereditary disorders of tubular
transport are no exception. Consequently, it s not
surprizing that, for example, three different mutant
alleles, each apparently at the same "cystinuria" gene
locus, occur among subjects with cystinuria [72]; and
that four mutant alleles, all apparently at the locus
specifying the shared transport system for imino
acids and glycine, are now required to explain the
different forms of familial renal iminoglycinuria [6,
109]; and that different alleles at two independent
gene loci controlling glucose transport are needed to
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explain glucose-galactose malabsorption and renal
glucosuria [39,40J. The discovery of two different
phenotypes in the pseudohypoparathyroidism trait,
one with blunted renal cyclic nucleotide formation
and one without, again argues for mutant alleles
which probably occur at different gene loci and which
control different components of the relevant trans-
port processes. It follows that recognition of genetic
heterogeneity will also help to direct the physician
toward more precise diagnosis, counselling and treat-
ment.
Appropriate dissection of tubular function in man
through genetic "probes" has revealed an important
general underlying theme. Loss of a specific transport
function rarely leaves the homozygous proband de-
void of all function for the particular transport in
question [160]. For example, homozygotes with renal
iminoglycinuria retain a significant fraction of pro-
line reclamation under endogenous conditions [109];
and homozygotes with severe type-A glucosuria re-
tain one-third of their maximum glucose reabsorptive
capacity in kidney and have lost none in the intestine
[39, 58]. These manifestations of "residual" transport
in mutants reflect functional redundancy in the mem-
brane carriers and in the genes which specify trans-
port options for solutes. The normal ontogeny of
tubular function in the postnatal period also reveals
diversity among carriers, some being present at birth,
others disappearing or appearing on schedule post-
natally during renal maturation [112, 161]. Genetics
and ontogeny, in combination with kinetic and chem-
ical probes [3, 6], have revealed a "horizontal" diver-
sity of membrane sites which allows them to dis-
tinguish the chemical identity of solutes; and a
"vertical" diversity which allows them to recognize a
solute differently when it is present at high or at low
concentration.
This diversity among solute transport mechanisms
thus provides an adaptive function which protects the
organism from the effect of transport mutations
[1601; it also provides alternate systems which can be
utilized in treatment. Replacement of solute has
been accomplished in several of the hereditary
tubulopathies. Phosphate replacement is a valuable
component of treatment in X-linked hypophospha-
ternia and the Fanconi syndrome; bicarbonate re-
placement can be achieved in several forms of RTA.
To know both the biological basis and the
symptomatic manifestations of the hereditary tubulo-
pathies ought to provide present-day students of
Mendel, Darwin and Garrod with the means to relax
selection effectively against these intriguing muta-
tions in man.
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